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Summary. A deficiency in the activity of uroporphyrino- 
gen decarboxylase (UROD),  the fifth enzyme of the 
haem biosynthetic pathway, is found in familial porphyria 
cutanea tarda (F-PCT) and hepatoerythropoietic por- 
phyria (HEP). A new mutation (R292G) and a deletion 
have been found in a pedigree with two HEP patients 
(two sisters). The R292G mutation was not detected in 
13 unrelated affected patients with F-PCT, so it appears 
to be uncommon. The possibility that the arginine 292 
may participate at the active site of the enzyme is dis- 
cussed. A summary of the 7 mutations/deletions found in 
the UROD gene with their frequency is presented. 
that is very rapidly degraded in the presence of cell 
lysate (de Verneuil et al. 1986a). Another point muta- 
tion (E167K, Romana et al. 1991) has been recently de- 
scribed in another HEP patient. Three different muta- 
tions have been described in F-PCT. Interestingly, one 
mutation occurs at the same position as the HEP G281E 
mutation, but involves the substitution of a Val rather 
than a Glu (Garey et al. 1989). Two splice site mutations 
in the UROD gene have also been described in F-PCT 
(Garey et al. 1990). 
In this paper, we describe the characterization of a 
new mutation and a deletion in two HEP patients from 
the same family. 
Introduction 
Hepatoerythropoietic porphyria (HEP) is a rare homo- 
zygous form of familial porphyria cutanea tarda (F-PCT) 
that occurs early in infancy (for a review, see Kappas et 
al. 1988). The characteristic enzyme deficiency is a pro- 
found decrease in the activity of uroporphyrinogen de- 
carboxylase (UROD),  the fifth enzyme of the haem bio- 
synthetic pathway (Elder et al. 1981; Lazaro et al. 1984), 
whereas the enzyme activity in F-PCT is about 50% of 
the normal level (Kushner et al. 1976; de Verneuil et al. 
1978). Evidence for heterogeneity in inherited UROD 
deficiency has been well documented at the protein level 
with CR IM (cross-reactive immunological material)-  
positive (presence of an abnormal immunologically de- 
tectable protein) and CRIM-negative (absence of the ab- 
normal protein) cases (Sassa et al. 1983; de Verneuil et 
al. 1984, 1986b; Toback et al. 1987; Fujita et al. 1987; 
Koszo et al. 1990). 
We have characterized the first mutation (G281E) in 
one of the CRIM-negative family leading to a protein 
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Materials and methods 
Cases studied 
The patients consisted of two sisters (patients I and II) with HEP 
from non-consanguineous parents of Caucasian origin (Holland) 
(Fig. 1). Neither parent had experienced any clinical symptoms of
the disease. Diagnosis of HEP was confirmed by enzymatic 
studies. UROD was measured on haemoglobin-free haemolysate 
5 
(ND) 
1 2 
s 
I 
(0.3) (0.4) 
Fig. 1. Family pedigree with results from enzymatic studies. Both 
parents (1 mother; 2father) are clinically unaffected. The children 
(3 patient I; 4 patient II) have clinical symptoms ofporphyria nd 
a porphyrin excretion pattern characteristic ofHEP. Individual 5 is 
a second egree relative of the father. Numbers in parentheses are 
UROD activities (normal values 4.8 + 1.2U/mg of protein; ND 
not done) 
with pentacarboxylic porphyrinogen I as substrate (de Verneuil et 
al. 1983). One unit of UROD activity is defined as the amount of 
enzyme preparation that catalyzes the formation of 1 nmol cop- 
roporphyrinogen I per h at 37~ in the standard assay medium. 
Results were as follows: father, 1.7 unit per mg of protein; mother, 
2.2; patient I, 0.4; patient II, 0.3; normal values, 4.8 + 1.2 (2 stan- 
dard deviations). 
In vitro amplification 
RNA was isolated from lymphocytes by non-ionic detergent lysis 
(Sambrook et al. 1989). Reverse transcription sequences ofcDNA 
were amplified in vitro in a mixture of 50 ~tl containing 70 mmol/1 
TRIS-HCL at pH 8.8, 1.5mmol/1 MgCI2, 0.1% Triton X-100, 
200 ~tmol each of dATP, dCTP, dGTP, dTTP, 20 pmoles of each 
primer (UDE 11:5'-CCGGAATTCAGTTACAGACAGCTG- 
ACC-3' and UDE 61: 5'-TGTGTTAGTGGTACTI'GAGGGTA- 
3) and 1 unit of Taq polymerase (Gibco BRL). The cDNA was de- 
natured for 3min at 95~ and amplified for 30 cycles ( lmin at 
94~ 1 min at 55~ i min 30 s at 70~ in a DNA Thermal Cycler 
(Perkin-Elmer). 
DNA was extracted from blood by the usual methods. A sam- 
ple of 200 ng of DNA was amplified in vitro in a mixture of 50 rtl 
containing 70mmol/1 TRIS-HCL at pH 8.8, 1.5mmol/1 MgCI2, 
0.1% Triton X-100,200 ~tmol each of dATP, dCTP, dGTP, dTTP, 
20 pmoles of each primer (UDI 70: 5'-GCAAGGCCCTCTGTA- 
GCCTGA-3' and UDE 62:5'-GTCCTGGAAACGATCAATC- 
3') and 1 unit of Taq polymerase (Gibco BRL). Conditions were 
identical to those used for the cDNA amplification. 
cDNA cloning and sequencing 
The polymerase chain reaction (PCR) products were subcloned 
into the pGEM7Zf+ vector (Promega Biotec, Madison, WI). The 
DNA was purified by gel filtration on an S-200 column (Pharmacia, 
Sweden) and subcloned into an EcoRI-HindIII-digested vector. 
Different independent clones were then sequenced by the dideoxy- 
chain termination method (Sequenase sequencing kit, USB Cor- 
poration). 
Oligonucleotide hybridization analysis 
Amplified fragments were slot-blotted onto a nylon membrane 
and then hybridized to allele-specific oligonucleotides (ASOs). 
The sequence of the two ASOs are as follows: 292N: 5'- 
AGAAAGCCCGGTAAGCC-3' and 292M: 5'-AGAAAGCCG- 
GGTAAGCC-Y. Probe labelling, hybridization (56~ and post- 
hybridization filter washes (58~ were carried out according to the 
method escribed previously (Grandchamp etal. 1989), except hat 
oligonucleotides and temperatures were varied as mentioned above. 
In vitro degradation studies 
RNA was made by transcribing cDNA in vitro using T7 RNA poly- 
merase after linearization of the plasmid with HindIII. The RNA 
was then translated in vitro in a micrococcal nuclease-treated rab- 
bit reticulocyte lysate in the presence of [35S] methionine (de Ver- 
neuil et al. 1986b). Aliquots (5 ~tl) of the translation mixture were 
incubated at 37~ for 0, 24, 48 and 80 h in the presence of 15 ~tl 
sonicated lymphoblastoid cell lysate (2 mg/ml). Translation pro- 
ducts were analysed by SDS (sodium dodecylsulphate) polyacryl- 
amide gel (10%) eleetrophoresis. 
Results 
The two pr imers used for the cDNA-PCR al lowed the 
ampl i f icat ion of  the cDNA sequence corresponding to 
ATG 
TGA 
I I 
1 1122 12~ 
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Fig. 2. Amplification of the UROD cDNA by PCR. Upper part 
schematic drawing of the cDNA with the two primers UDEl l  and 
UDE62 used for the amplification. Lower part PCR amplification 
products of cDNA derived from lymphocytes of a normal indi- 
vidual (lane 3) and of patient I (lane 2). Arrowhead in icates the 
position of the amplified fragment (1165 bp) 
Fig. 3A, B. Characterization f the R292G mutation at the genomic 
level. A PCR amplification products of genomic DNA using the 
two primers UDI70 (in intron 7) and UDE62 (exon 10). Lanes 2-5 
correspond to the amplification of genomic DNA from a control, 
the father, the mother and patient I. Lane 0 no DNA added to the 
amplification mixture. B Dot-blots of the amplified fragments with 
the normal (292N) and the mutant (292M) oligonucleotides. Lane 
1 amplified DNA from a relative of the father; lane 6 amplified 
DNA from patient II. Other lanes show amplified DNAs identical 
to those in the same lanes in A. The sequences of the two ASOs 
are as follows: 292N, 5'-AGAAAGCCCGGTAAGCC-3'; 292M, 
5'-AGAAAGCCGGGTAAGCC-3' 
the entire coding region of the prote in  (see Fig. 2, upper  
part) .  Ampl i f ied  fragments of identical  size were ob- 
ta ined both with pat ient I and control  cDNAs  (Fig. 2, 
lower part) ,  Hybr id izat ion with ASOs  corresponding to 
the 3 previously known point mutat ions (G281E, de 
Verneui l  et al. 1986a; G281V, Garey  et al. 1989; E167K, 
Romana et al. 1991) revealed no hybr id izat ion (data not 
shown),  leading to the conclusion that these pat ients 
carry (an)other  mutat ion(s) .  
Cloning and sequencing of the ampl i f ied f ragment 
from pat ient  I revealed that two independent  clones 
carry a C to G change at nucleot ide 892, leading to a Arg  
292--~Gly substitut ion (R292G) in the protein.  No other  
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Fig.4. Blot hybridization of human genomic DNA. DNA (7ftg) 
was digested with Pstl and electrophoresed in a 1% agarose gel. 
The DNA was denatured, transferred to a nylon membrane 
(Hybond-N +, Amersham) and hybridized with either [32p] UROD 
cDNA or porphobilinogen deaminase (PBGD) cDNA probes. 
Lanes 1-3 DNA from the father, the mother and a control, respec- 
tively 
base change was found. We confirmed that this nucleo- 
tide substitution suppresses a Sinai site (5 ' -CCCGGG-3')  
in the cDNA by direct digestion of the PCR-amplified 
products with Sinai (data not shown). This restriction 
site (position 890-895 on the cDNA; see Romeo et al. 
1986 for the normal human sequence) corresponds to the 
exon 8-intron 8 boundary (Romana et al. 1987a) and is 
not conserved in the genomic DNA. We therefore de- 
cided to confirm the mutation at the gene level by hy- 
bridization of an amplified genomic DNA fragment of 
860bp (from intron 7 to exon 10) with ASOs (Fig. 3), 
The normal oligonucleotide probe (292 N) hybridized to 
DNA from normal controls. The mutant probe (292 M) 
hybridized to amplified DNA from the patient, whereas 
no signal was found with the normal oligonucleotide, 
confirming the existence of the mutation at the genomic 
level. 
At this point of the study, two hypotheses could have 
explained the results: either patient I is homozygous for 
the R292G mutation or she is heterozygous for this mu- 
tation and carries a deletion of the UROD gene. A fam- 
ily study was then undertaken to clarify this point. 
Amplified genomic fragment from the mother hybrid- 
ized with both probes (292N and 292M), confirming 
that she carries the R292G mutation. In contrast, the 
amplified fragment from the father hybridized only with 
the normal probe: this result indicates that the father 
carries a deletion that is not detectable by our PCR 
amplification. We then performed a Southern blot anal- 
ysis in order to characterize the deletion of the UROD 
gene (Fig. 4). We could not find any fragments of an ab- 
normal size from the DNA of the father with three dif- 
ferent restriction enzymes (EcoRI ,  HindI I I ,  PstI). How- 
ever, a weaker signal was found for the specific fragment 
from the father compared with the mother, or a normal 
control, confirming the existence of a deleterious allele 
from the father. 
In vitro translated [35S]-labelled normal and mutant 
UROD proteins were exposed to lymphoblastoid cell 
lysates (for 0 h, 24 h, 48 h and 80 h) and then subjected to 
electrophoresis on polyacrylamide SDS gels. No signifi- 
Mutations Original description Frequency Frequency 
in HEP in F-PCT 
HEP 
Gly281-*Glu Verneuil et al. 1986 8/14 0/20 
HEP 
Glu167~Lys Romana et al. 1991 2/14 0/15 
HEP 
Arg292-*Gly This paper 1/14 0/13 
HEP 
Large deletion This paper 1/14 - -  
F- PCT 
Gly281-*Val Garey et al, 1989 0/14 1/20 
F-PCT 
Exon 6 deletion Garey et al. 1990 0/14 4/20 
F-PCT 
Exon 6 deletion Garey et al. 1989 0/14 1/20 
E 167"-~K G28 I'-,V/E 
ATG 517 860 Stop 
k._l I I 892 del.ex3 del.ex6 
R292~G 
Fig. 5. Summary of the different mutations/deletions found in the 
UROD gene with their frequency. The lower part represents a 
schematic drawing of the cDNA with the position of the initiating 
codon ATG (nucleotides 19-21) and the STOP codon TGA (nu- 
cleotides 1120-1122). Numbers' along the figure give the position 
of the mutations on the cDNA. The position of the two exon 
deletions are also shown. E 167--~K: Glu167---~Lys mutation; 
G281~V/E: Gly 281---~Val nd Gly 281--~Glu mutations: R292---~G: 
Arg292--~Giy mutation. The upper part of the figure gives the list 
of the different mutations/deletions fou din HEP and F-PCT, and 
the frequency of each mutation/deletion (two mutated alleles for 
the HEP patients, one mutated allele for the F-PCT patients) 
cant difference in degradation between the normal and 
the mutant protein was found. 
We checked for the presence of the R292G mutation 
in 13 unrelated F-PCT patients by hybridization of spe- 
cific genomic fragments with the ASOs. None of the 13 
tested patients carries the mutation. 
Figure 5 is a summary of the different mutations/dele- 
tions found in the UROD gene in HEP and F-PCT. The 
frequency of the mutations has been calculated from 
seven HEP patients from 7 unrelated families (14 mu- 
tated alleles) and from 13-20 F-PCT patients (13-20 
mutated alleles). This frequency is not accurate because 
of the small number of families (the disease is very rare) 
and because of possible consanguinity. However, we can 
conclude from these results that a great heterogeneity 
exists among the mutations responsible for HEP or 
F-PCT in humans. Two different mutations (the G281E 
mutation for HEP and a splice site mutation that causes 
the deletion of exon 6 in F-PCT) appear to be more com- 
mon. 
Discussion 
The present study describes a molecular analysis of the 
UROD gene in two new HEP patients. The strategy that 
1 rUROD MEANGLGLQNFPELKNDTFLRAATGEETDYTPVWSMRQAGRYLPEFRETR 
hUROD MEANGLGPQGFPELKNDTFLRAAWGEETDYTPVWSMRQAGRYLPEFRETR 50 
Svnec  M . . . .  VASSSLPRL  . . . . .  LRAARGEVLDRPPVWMMRQAGRYMKVYRDLR 
1 AA-QDFFSTCRSPEACCELTVQPLRRFPLDAAI IFSDILVVPQALAMEVTMVPGKG 
2 AA-QDFFSTCRSPEACCELTLQPLRRFPLDAAI IFSDILVVPQALGMEVTMVPSKG 105 
3 DKYPGFRERSETPELAIE ISLQPFRAFKPDGVILFSDI  
1 ps FPEPLREERDLEALRDPAAVAS ELGYVFQAI  TLTRRRLAGRVPL IGFAGAPWTL 
2 pS FPEPLREEQDLEALRDPEWAS ELGYVFQAI  TLTRQRLAGRVPL I  GFAGAPWTL 161 
1 MTYMVEGGSFKTMAQAKRWLYQKPVASHKLLGILTHALVPYL IGQVAAGAQALQLF  
2 MTYMV_EGGGSSTMAQAKRWLYQRPQASHQLLRILTDALVPYLVGQVVAGAQALQLF  
1 ESHAGHLGSELFSKFALPY IRDVAKRVKAGLQKAGLTRMPMI IFAKDGHFALEELA 
2 ESHAGHLGPQLFNKFALPY IRDVAKQVKARLREAGLAPVPMI IFAKDGHFALEELA 
1 QAGYEVVGLDWTVAPKKARECVGKTVTLQGELDPCALYASEEE IGRLVQQMLNDFG 
2 QAGYEVVGLDWTVAPK~ECVGKTVTLQGNLDPCALYASEEEIGQLVKQMLDDFG 
4 reav  
1 pQRYIANLGHGLYPDMDPEHVGAFLDAVHKHSRLLRQN 
2 PHRYIANLGHGLYPDMDPEHVGAFVDAVHKHSRLLRQN 367 
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Fig. 6. Amino acid sequence alignment of rat 
217 (lane 1), human (lane 2) and bacterial ( ane 3; 
from Kiel et al. 1990) enzymes. The one-letter 
code is used. The numbers to the right of the 
273 sequence indicate the position of the residue 
relative to the N-terminal methionine (position 1) 
of the human enzyme. The conserved arginines 
(R) are indicated by stars and the mutated (292) 
329 arginine is underlined. The position of the two 
previously determined 167 and 281 mutations i
also underlined. The four residues (lane 4) 
correspond tothe yeast sequence (R. Labbe-Bois, 
personal communication). Dashes represent gaps 
introduced to maximize the homology 
we used is as follows: extraction of total RNA from the 
lymphocytes of one of the patients allowed us to amplify 
in vitro the entire coding sequence in a single step of 
PCR. Because of the presence of amplified fragments 
that were normal in size, we have been able to determine 
that a point mutation (R292G) is present in the patient. 
This mutation has been confirmed at the DNA level by 
specific amplification of a part of the gene (from intron 7 
to exon 10) and by hybridization with ASOs. A familial 
study revealed that the R292G mutation is present in the 
DNA of patient II and the mother, but not the father. 
Illegitimacy was excluded by a study of restriction frag- 
ment length polymorphisms of the HLADQ locus in the 
family. Because amplified DNA from both children did 
not hybridize with the normal 292N probe, the only ex- 
planation of the profound deficiency present in both 
children and the 50% deficiency present in the father's 
blood is a deletion of the UROD gene on one allele. 
Southern blot analysis did not detect any abnormally 
sized UROD gene fragments, leading to the conclusion 
that the deletion is large, at least more than 3 kb (corre- 
sponding to the size of the UROD gene explored by the 
cDNA probe). Chromosome walking from the 5' end 
and 3' end of the gene will be needed to characterize the 
deletion further. 
The mutation results in the presence, in the abnormal 
protein, of a glycine residue instead of an arginine. 
Interestingly, this arginine is a conserved amino acid in 
the rat (Romana et al. 1987b) and in yeast proteins 
(R. Labbe-Bois,  personal communication) (Fig. 6). 
Kinetic data of crude or purified normal human, chicken 
and bovine UROD suggest hat there may be between 2
and 4 active sites for the different sequential decarboxy- 
lations of uroporphyrinogen to coproporphyrinogen (de 
Verneuil et al. 1980, 1983; Kawanishi et al. 1983; Straka 
and Kushner 1983). Experiments using SH-inactivating 
agents uggest that at least one cysteine is involved in the 
decarboxylation (de Verneuil et al. 1983). It is probable 
that basic amino acids are also involved in the catalytic 
site or are important for the integrity of the protein, be- 
cause of the high conservation of these residues (Fig. 6). 
Chemical modification of cationic residues present in 
different enzymes of the haem pathway results in the 
rapid inactivation of the protein. This has been demon- 
strated for ferrochelatase (Dailey and Fleming 1986) and 
uroporphyrinogen III synthase (Hart et al. 1985) for 
arginyl residues, and for porphobilinogen deaminase 
(Miller et al. 1989) and aminolevulinate dehydratase 
(Gibbs and Jordan 1986) for lysyl residues. These con- 
siderations raise the possibility that the arginine 292 may 
participate at the active site of the enzyme by the forma- 
tion of ionic bonds with the different acetic and/or pro- 
pionic side chains of the substrate uroporphyrinogen. 
Isolation of normal and mutated proteins from over-ex- 
pressing strains hould allow us to study the three dimen- 
sional structure of the protein and to determine the dif- 
ferent residues involved in the active site(s). 
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